Skip to content
The Injury Atlas
FANC

Fanconi Syndrome

Global failure of proximal tubule reabsorption — glucosuria, phosphaturia and acidosis, classically from ifosfamide.

11agents

Where it strikes

Proximal Tubule

Bulk reabsorption + drug uptake (OCT2, OATs)

See it on the nephron

Agents’ overall severity

Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.

Severe· 3Moderate· 5Mild· 3

Agents’ overall reversibility

Often irreversible· 1Partially reversible· 4Variable· 2Reversible· 4
Does the kidney recover? Cross-drug outcomes

Agents’ onset window

How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.

Acute (days)· 4Subacute (weeks)· 2Delayed (weeks–months)· 1Variable· 4

Real-world reporting for this lesion

FAERS across all lesions →

How disproportionately fanconi syndrome is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.

3Corroborated

Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.

6Documented, FAERS-silent

Documented in a profile with no reporting signal. 6 of 6 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.

10Not attributable

A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.

10Reported by name

The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.

Order
  1. DoxifluridineAntimetabolite (oral 5-FU prodrug) · FAERS only36.82 (9.15–148.19) · n=2 Reporting signal, fragile (few reports).
  2. IfosfamideOxazaphosphorine alkylator31.95 (27.43–37.22) · n=173 Reporting signal.
  3. Dactinomycin (actinomycin D)Antitumor antibiotic · FAERS only18.99 (10.49–34.36) · n=11 Reporting signal.
  4. Zoledronic acidBisphosphonate11.47 (9.87–13.32) · n=179 Reporting signal.
  5. ZolbetuximabAnti-Claudin-18.2 monoclonal antibody · FAERS only9.97 (3.74–26.61) · n=4 Reporting signal, fragile (few reports).
  6. BicalutamideNonsteroidal antiandrogen · FAERS only7.23 (5.02–10.42) · n=29 Reporting signal.
  7. TazemetostatEZH2 inhibitor · FAERS only7.02 (2.26–21.81) · n=3 Reporting signal, fragile (few reports).
  8. EtoposideTopoisomerase II inhibitor · FAERS only6.16 (5.13–7.39) · n=119 Reporting signal.
  9. Interleukin-2 (high-dose)Cytokine · FAERS only6.01 (1.50–24.07) · n=2 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
  10. BusulfanAlkylator · FAERS only4.30 (2.71–6.83) · n=18 Reporting signal.
  11. CisplatinPlatinum agent4.29 (3.47–5.29) · n=88 Reporting signal.
  12. DoxorubicinAnthracycline · FAERS only3.97 (3.25–4.83) · n=100 Reporting signal.
  13. CarboplatinPlatinum agent · FAERS only3.57 (2.97–4.28) · n=120 Reporting signal.
  14. AzacitidineHypomethylating agent2.52 (1.63–3.91) · n=20 * Reporting signal, on terms consistent with the lesion rather than naming it.
  15. VemurafenibBRAF inhibitor0.63 (0.16–2.53) · n=2 No reporting signal.
  16. LenalidomideImmunomodulatory drug (IMiD)0.48 (0.37–0.63) · n=55 No reporting signal.
  17. Trastuzumab deruxtecanAntibody-drug conjugate (HER2/DXd)0.35 (0.05–2.46) · n=1 No reporting signal.
  18. ImatinibBCR-ABL TKI0.17 (0.04–0.69) · n=2 No reporting signal.

reporting odds ratio (log) — no signal left of the dashed line at 1.0

No ratio — no FANC reports, or too few (count in brackets): Nirogacestat, Streptozocin

All 10 agents documented with FANC in the atlas are shown whether or not FAERS flags them, plus the 19 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib)) are not asked of FAERS; their member agents are ranked individually. 23 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.

Management approach

Full framework →

Supportive electrolyte and acid–base repletion; often partially irreversible, so prevention (cumulative-dose limits) matters.

Drug-level levers

  • Hold or avoid further exposure once Fanconi features appear.
  • Respect cumulative-dose limits; use caution in young children and after prior cisplatin exposure.

Pharmacologic toolkit

  • Electrolyte repletion — Phosphate, bicarbonate or citrate (for proximal renal tubular acidosis), and potassium replacement.
  • Supportive — Monitor growth in children; some proximal tubular dysfunction persists long-term.

When to biopsy

Usually clinical (glucosuria with normal serum glucose, phosphaturia, proximal RTA); biopsy not routinely required.

Monitoring

  • · Phosphate, bicarbonate, potassium, glucose
  • · Growth in children

Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.

Signature offenders

3

Agents for which fanconi syndrome is the defining renal lesion.

IfosfamideAcute tubulopathy during therapy; chronic Fanconi/CKD can emerge months–years later.Subclinical tubular dysfunction is common while overt Fanconi is not, and the gap is the point. Prospectively, high-dose ifosfamide in children and young adults was associated with a 4% incidence of Fanconi-like syndrome, though every patient showed acute, reversible subclinical nephrotoxicity (Ho 1995, PMID 8625085). In 183 children investigated prospectively at least 5 years out — none of whom received any platinum, so the toxicity is attributable — the tubular threshold for phosphate was reduced in 24% and glycosuria detected in 37%, yet glycosuria exceeded 0.5 g/24 h in only 5%, bicarbonate and calcium were normal in every patient, and 89.5% had normal tubular function overall at a median 10 years. GFR was abnormal in 21.5%. Ifosfamide dose and time since therapy both predicted tubulopathy. Rates elsewhere span 0% to 84% depending on the definition and cohort used, so a single figure is only meaningful with its threshold attached.SevereStreptozocinWithin weeks of therapy; worsens with cumulative dose; abrupt AKI possible on re-challenge.Nephrotoxicity is the major dose-limiting toxicity; transient proteinuria, tubular dysfunction and azotemia are common and a sizable minority develop clinically significant renal impairment, though precise rates are not uniformly quantified. Reported rate: decrease in estimated glomerular filtration rate of at least 25% during treatment in 30% — 111 patients (27 prospective + 84 retrospective) with locally advanced or metastatic well-differentiated digestive… (Legoux 2021, PMID 33751987).SevereAzacitidineDuring treatment cycles (days to weeks).Proximal tubular dysfunction (proximal/type 2 renal tubular acidosis, polyuria, and glucose/amino-acid/electrolyte wasting) was described with higher-dose azacitidine; with current low-dose subcutaneous/IV regimens overt AKI is uncommon and renal incidence is not well quantified (case-level).Moderate

Also associated

8

Agents that cause fanconi syndrome as a secondary pattern alongside a different signature lesion.

CisplatinAcute — creatinine peaks ~day 4–7; magnesium wasting can persist for months.AKI (creatinine up more than 25% within 30 days of the first cycle) in 31.5% of 821 adults across tumor types — a cohort restricted to patients who survived at least 5 years (Latcha 2016, PMID 27073199). Hypomagnesemia in up to 90% if no corrective measures are taken (Lajer 1999, PMID 10212589).SevereZoledronic acidAcute — days to weeks after infusion(s).Nephrotoxicity is the dose-limiting toxicity but largely avoidable. Reported rate: renal toxicity in 17% of 852 patients with newly diagnosed multiple myeloma given zoledronic acid 4 mg every 4 weeks, versus 10% on denosumab (Raje 2018, PMID 29429912).ModerateTrastuzumab deruxtecanVariable; reported during ongoing therapy, sometimes resolving over months after discontinuation.Renal data are emerging and under-published. AKI/proteinuria are reported at case level; a reversible proximal-tubule Fanconi syndrome (glucosuria, phosphate/potassium wasting, non-anion-gap acidosis) has been described and attributed to the deruxtecan payload. Renal-specific incidence is not quantified.ModerateLenalidomideVariable; azotemia reported from weeks to several months after initiation.AKI/azotemia is uncommon but recognized, described mainly in case series of plasma-cell dyscrasias with underlying renal insufficiency; not reliably quantified as an incidence. Rare Fanconi syndrome and TMA are reported. Because ~80% of lenalidomide is renally cleared as unchanged drug, accumulation in renal impairment is the dominant driver of toxicity, including myelosuppression.ModerateVemurafenibEarly — most cases arise within the first weeks to three months of therapy (all AKI events in the Teuma cohort occurred in the first trimester of treatment); later onset is uncommon.Clinically meaningful AKI is a recognized but variably quantified effect, and vemurafenib is the strongest renal offender of the BRAF/MEK class. Small serum-creatinine rises are common and usually low-grade; overt AKI produced the first case series of 8 patients with significant-to-severe renal insufficiency (Launay-Vacher, Cancer 2014) and 132 vemurafenib AKI reports to FDA FAERS over 3 years, far exceeding dabrafenib's 13 (Jhaveri, JAMA Oncol 2015). The monotherapy denominator comes from a retrospective single-center cohort of 74 patients with BRAF-V600-mutant metastatic melanoma, with creatinine measured before treatment, monthly on treatment and 3 months after stopping: 44 of 74 (59.5%) met the KDIGO threshold of a 1.5-fold creatinine rise, and 40 of those 44 (91%) were stage 1. Read that figure with its definition attached — it is creatinine-based, and BRAF/MEK inhibitors also blunt tubular creatinine secretion, so a share of any such cohort is pseudo-AKI rather than tubular injury; the authors biopsied two stage-1 patients to demonstrate real tissue damage. Men were over-represented among the AKI-positive patients (75% versus 40%). Adding a MEK inhibitor lowers it substantially: in the companion cobimetinib cohort 9 of 38 (24%) developed AKI, all within three months and mostly stage 1-2, about a 60% reduction versus monotherapy.ModerateBRAF / MEK InhibitorsAcute–subacute during therapy.Pharmacovigilance shows vemurafenib > dabrafenib. Mild creatinine elevation common, serious AKI uncommon. Reported rate: acute kidney injury in 21% — 199 patients who received dabrafenib/trametinib in a single large US healthcare system between 2010 and 2019… (Seethapathy 2022, PMID 33355659).MildImatinibEdema early; tubular dysfunction and eGFR decline develop over months to years.Periorbital/peripheral edema and fluid retention are common. Clinically meaningful renal injury is uncommon: long-term front-line imatinib is associated with a modest, measurable decline in eGFR over years, while proximal tubular dysfunction (hypophosphatemia, aminoaciduria, rare Fanconi syndrome) and AKI (including rare urate nephropathy from disease cytoreduction) are described at the case level.MildNirogacestatDuring therapy; not well characterized.Hypophosphatemia occurred in 42% of nirogacestat-treated patients in the DeFi trial, alongside other electrolyte disturbances; the characteristic DeFi-trial toxicities were diarrhea, rash, nausea, fatigue and ovarian dysfunction. Beyond the phosphate signal, renal-specific incidence is not well quantified.Mild